Design Therapeutics, Inc.
General ticker "DSGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $279.8M (TTM average)
Design Therapeutics, Inc. follows the US Stock Market performance with the rate: 46.4%.
Estimated limits based on current volatility of 4.3%: low 9.11$, high 9.93$
Factors to consider:
- Total employees count: 54 (-6.9%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital for product development, Regulatory and compliance, Market competition, Labor/talent shortage/retention, Intellectual property risks
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.83$, 9.56$]
- 2025-12-31 to 2026-12-31 estimated range: [2.81$, 7.31$]
Financial Metrics affecting the DSGN estimates:
- Negative: with PPE of -7.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.28 <= 0.33
- Positive: Shareholder equity ratio, % of 96.03 > 63.39
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term DSGN quotes
Long-term DSGN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $67.59MM | $78.19MM | $62.38MM |
| Operating Income | $-67.59MM | $-78.19MM | $-62.38MM |
| Non-Operating Income | $4.29MM | $11.33MM | $12.79MM |
| R&D Expense | $48.61MM | $57.06MM | $44.35MM |
| Income(Loss) | $-63.31MM | $-66.86MM | $-49.59MM |
| Profit(Loss)* | $-63.31MM | $-66.86MM | $-49.59MM |
| Stockholders Equity | $327.31MM | $277.69MM | $242.10MM |
| Assets | $341.14MM | $289.64MM | $252.09MM |
| Operating Cash Flow | $-51.32MM | $-58.56MM | $-43.10MM |
| Capital expenditure | $0.92MM | $0.26MM | $0.34MM |
| Investing Cash Flow | $-220.99MM | $52.54MM | $43.95MM |
| Financing Cash Flow | $0.23MM | $0.72MM | $0.51MM |
| Earnings Per Share** | $-1.14 | $-1.19 | $-0.88 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.